Robert Daniels

Allergan to Acquire Elastagen to Access Next Generation Injectable Portfolio

Sydney-based tropoelastin biotech Elastagen agreed to an Allergan takeover offering US$95 million upfront plus contingent payments; the GBS Ventures-backed company previously drew MDF and federal grant funding.

Also GBS Ventures·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Startup Daily·Startup Daily·Startup Daily

Cell Innovation Partners, Japanese venture group, invests in Elastagen as part of a Second Close to the Series B Equity Financing.

Cell Innovation Partners invested A$1 million in Sydney biotech Elastagen within a second close of its A$14 million Series B, with AMOREPACIFIC Ventures, Korea Investment Partners and the Wellcome Trust also joining the round.

Elastagen Completes A$13m Series B Equity Financing

Sydney clinical-stage medical company Elastagen closed a A$13 million Series B, adding KIP, AMOREPACIFIC Ventures and Wellcome Trust to its existing backers; KIP's Sangwoo Lee joined the board.

Elastagen Expands Clinical Program for Elastin Products.

Sydney medical device company Elastagen completed a first-in-human study of its synthetic elastin skin products and plans two further trials, targeting a European launch in early 2013.